John Peters
John is a results-focused business development executive, operating in the active lifestyle, youth sports/fitness technology industries. John enjoys problem solving and has experience advising entrepreneurs and companies in the following areas: youth sports, venture capital, private equity, sporting goods, fitness and sports technology companies, and retail.
John has been immersed in innovations driving the fitness and sports industries forward, largely due to launching the Sports Technology Marketplace for the Consumer Electronics Show (CES) in 2014. John is an advisor to several sports technology accelerators, angel groups, venture capital funds and startups. John also created the SFIA Startup Challenge in 2016 – an international pitch contest that has attracted 300+ companies to apply and in just 3 years, the 16 companies who have been selected as finalists, have raised $135M+ in venture funding. John is a frequent keynote speaker on innovation and trends in fitness, technology and youth sports. John also was responsible for launching the ‘Future of Sports’ event franchise for UBS Group on Wall Street.
John recently launched the Sport Lifestyle Podcast with a focus on the industry, featuring influencers driving the sports, footwear, fashion, retail and sports tech markets forward.
In 2016, John was named a 40 Under 40 by Sporting Goods Business, an annual award that has featured industry leaders such as Kevin Plank, Sarah Robb O’Hagan, Josh Luber and many other industry executives.
Ivan Wasserman
Ivan Wasserman is the Managing Partner of the leading regulatory, intellectual property, and litigation law firm Amin Talati Wasserman LLP. Noted for expertise in foods, dietary supplement, and cosmetics, Ivan and his team represent clients before the FDA, the FTC, the CPSC, State Attorneys General, and in class action litigation. Ivan also serves as counsel to the International Probiotics Association, is a frequent speaker and author on regulatory issues, and has been included in Best Lawyers in America from 2007 to 2019.
Fredrick Allain
John Simon Craw
Dr Kamal Azzaoui
Saverna Therapeutics’ main aim is to discover and develop new molecules for therapeutically areas such inflammation, oncology and infectious diseases. They use a platform based on Fragment Screening using NMR coupled with Machine Learning to identify molecules targeting none coding RNAs.
Dr John Schneekloth
